The Europe market for Cancer therapy market has been estimated at USD 7.6 billion for the year 2016 and is projected to reach USD 14.1 billion by the end of 2021 at a CAGR of 13 % during the forecast period from 2016 to 2021. Cancer is a malignant growth caused by uncontrolled division of cells in a part of body. Cancer is the leading cause of death and the incidence rates are increasing annually. Due to this, demand for quality cancer treatments also has risen dramatically which is contributing to the growth of the market.
The end-users of this market are clinics, hospitals and research centers. Lung cancer, breast cancer, colorectal cancers, ovarian cancer, head and neck cancer, stomach cancer and liver cancer are some of the common cancers increasing the treatment options in Europe.
Increasing incidences of cancer, aging population, growing demand for advanced therapies, patent expiry of leading drugs, government initiatives and increasing public awareness about diseases and treatment options are the factors driving the growth of Europe market. On other hand, high prices of therapies, side-effects caused during treatment, change in reimbursement policies and stringent regulatory issues are the factors restraining the market growth.
The market for Cancer therapy in Europe is segmented based on the type of therapy which includes Chemotherapy (Marketed drugs and drugs in pipeline), Radiotherapy, Surgery, Hormone therapy, Targeted cancer therapy, Immunotherapy (Monoclonal antibodies, cancer vaccines and non-specific immunotherapy) and Combination therapy. Chemotherapy, Radiation therapy and Combinational therapy are increasingly available in European regions. However, chemotherapy is well established and largest segment of the therapeutics market.
Based on geography, Europe market is segmented into France, UK, Germany, Russia, Italy, Spain & Portugal, Scandinavia and BENELUX. Europe is the second largest region dominating the market, after North America. UK contributes a larger share to the European cancer therapeutics market.
Many players in this market are trying to expand their product portfolio in order to top the global market. While few companies are entering into the market by acquisitions, top companies are expanding their growth in this market by acquiring other companies. Few companies adopted product innovation and new product launches as its key business strategy to ensure its dominance in this market. Roche is developing biggest number of combinational therapies. Major companies discussed in the report are Roche, Merck, Bristol-Myers Squibb, Novartis, Celgene, Teva, Pfizer, Astra Zeneca, GlaxoSmithKline PLC, GPC Biotech AG, Genentech Inc., Osi Pharmaceuticals Inc. and Janssen.
Key Deliverables in the Study